Rick Doblin blasts FDA on rejection of Lykos MDMA drug

It’s been a tough week for the psychedelics pioneer Rick Doblin. 

First, the Meals and Drug Administration declined to approve the MDMA-assisted remedy for post-traumatic stress dysfunction developed by Lykos Therapeutics, an organization that he based. The subsequent day, the journal Psychopharmacology retracted three research on the remedy, by which many authors have been related to Lykos or the nonprofit Doblin based, the Multidisciplinary Affiliation for Psychedelic Research (MAPS). 

On Thursday, Lykos introduced it could reduce 75% of its workers — and Doblin left the corporate’s board. Now, MAPS is slicing 33% of its personal 42-person workers, it mentioned, in an effort to preserve assets because it hones its focus to drug decriminalization and globalizing entry to MDMA.